The FDA has issued a warning about counterfeit Ozempic medications, sharing the lot numbers and serial numbers of products ...

Novo Nordisk, the maker of Ozempic and Wegovy, has also jumped into the legal fight —this time by intervening in the OFA’s lawsuit against the FDA. The company supports the agency’s move to restrict ...

The agency and Novo Nordisk, which makes Ozempic, said Monday that they had learned about "several hundred units" of the drug ...

With the investment, the production capacity will have "a considerable ... the active ingredient in Ozempic and Wegovy. Novo ...

SYNT-101 offers a novel approach to weight loss by temporarily altering nutrient absorption in the small intestine. Unlike ...

The US Food and Drug Administration (FDA) on Monday urged patients and healthcare providers to verify the authenticity of ...

While much of the recent GLP-1 saga has been written in the U.S., Novo Nordisk continues to expand its semaglutide empire ...

In a trial, the daily GLP-1 pill showed "significant" results and similar side effects to injectable GLP-1 drugs like Ozempic and Mounjaro, the pharmaceutical company says.

Two studies suggested the diabetes/weight-loss drug may have a beneficial side effect—but more work is needed to confirm this.

Current developments in the health sector include Novo Nordisk's warning about counterfeit Ozempic in the US, Sandoz's antitrust lawsuit against Amgen, and rising concerns in the biotech industry due ...